|
| Chemical agents | Models | Involved pathway | Effect | Reference |
|
| Resveratrol | OVX- and D-gal- induced AD rat model | SIRT1/NF-κB p65 | Suppression of Aβ and MMP-9 | Zhao et al. [105] |
| Resveratrol | AD mouse model induced by Aβ1–42 | SIRT1/AMPK/PGC-1α/NLRP3/NF-κB | Improvement of cognitive deficits | Qi et al. [157] |
| Resveratrol | Tg2576 mouse AD model | SIRT1 | Improvement of learning and memory, suppression of neural apoptosis | Wang et al. [163] |
| Resveratrol | Diabetes and AD rat model | SIRT1 | Improvement of memory deficits | Ma et al. [164] |
| Resveratrol | APP/PS1 AD mice | SIRT1 | Decrease of senile plaques and antioxidant effects | Dong et al. [165] |
| Resveratrol | APP/PS1 AD mice | SIRT1/ERK1/2 | Improvement of learning and memory and decrease of Aβ | Cao et al. [166] |
| Resveratrol | APP/PS1 AD mouse model | SIRT1/AMPK | Improvement of memory loss and decrease of amyloid burden | Porquet et al. [167] |
| Resveratrol | AD rat model induced by Aβ1–42 | SIRT1/CREB | Improvement of spatial, learning, and memory | Wang et al. [168] |
| — | 3xTg AD mouse model | SIRT1/BDNF | SIRT1-transgenic mice improve cognitive behavior and decrease Aβ and tau pathology | Corpas et al. [169] |
| SLAB51 | 3xTg AD mouse model | SIRT1 | Antioxidant effects | Bonfili et al. [170] |
| 24-OH | hTau mice | SIRT1 | Decrease of hyperphosphorylated tau protein | Testa et al. [171] |
| Acetylshikonin | D-galactose-induced AD mouse model | SIRT1/p53/p21 | Improvement of cognitive impairment and hippocampus senescence | Li et al. [172] |
| Melatonin | Aβ-induced AD mouse model | SIRT1/TFAM | Improvement of memory and hippocampal cell damage | Ansari Dezfouli et al. [173] |
| Dihydromyricetin | Aβ-induced AD rat model | AMPK/SIRT1 | Improvement of cognitive function and suppression of inflammatory responses and cell apoptosis | Sun et al. [174] |
| Salidroside | D-gal-induced AD rat model | SIRT1/NF-κB | Suppression of inflammatory responses | Gao et al. [175] |
|
